新华财经上海12月24日电（记者魏雨田）2025年，私募机构参与A股定增的热情高涨。据私募排排网统 计数据显示，按定增上市日口径计算，截至12月23日，全年共有52家私募机构积极布局定增市场，投资 覆盖58只A股标的，合计获配金额达59.8亿元，较2024年同期的48.43亿元增长23.48%；以当日收盘价测 算，目前这些定增项目已为私募带来27.24亿元的整体浮盈，浮盈比例高达45.55%。 李春瑜进一步分析称，电子行业作为AI算力、半导体、汽车电子、消费电子等创新领域的核心载体， 既受益于国产替代的持续推进，又在全球市场具备竞争优势。2025年，随着AI与机器人硬件迭代加 速、终端需求逐步回暖，叠加政策端持续扶持，电子行业的盈利能力与成长确定性显著增强。从定增投 向来看，电子企业募资多用于产能扩张、技术研发与产业链整合，这与私募机构长期价值投资理念高度 契合；同时，电子板块估值修复明显、浮盈空间可观，进一步强化了私募的配置意愿。 "2025年A股市场企稳回升与政策红利形成共振，定增项目的折价优势为私募机构提供了天然的安全 垫，叠加多元化的退出渠道，使得定增策略吸引力进一步增强。"排排网集团旗下融智投资FO ...

MetaX Integrated Circuits soared on its trading debut in Shanghai as investors piled into the second Chinese producer of graphics processing units (GPUs) to go public this month amid optimism about China's push for self-sufficiency in semiconductors and artificial intelligence. The shares of the Shanghai-based company surged 693 per cent from the offer price to 829.90 yuan at the close on Wednesday on the technology-heavy Star Market, making the five-year-old company the third-best performing debut on the ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission of Hong Kong take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Chaozhou Three-Circle (Group) Co., Ltd. 潮州三環（集團）股份有限公司 (the "Company") (A joint stock company incorpor ...

Summary of China Healthcare Conference Call Industry Overview - The conference call focused on the **China healthcare market**, highlighting significant transformations driven by DRG/VBP policies, domestic product substitution, and AI adoption in clinical workflows [1][4][5]. Key Insights AI Adoption - **AI Integration**: 86% of surveyed professionals are using AI-enabled medical devices or software, with hospitals budgeting an average of **Rmb6 million** for AI in 2025, expected to increase in 2026 [2][9][14]. - **Primary Applications**: The main uses of AI are in medical imaging and clinical decision support, enhancing diagnostic accuracy and saving time [10][12]. Hospital Procurement and Stimulus - **Procurement Recovery**: 64% of hospitals received stimulus funds, with a median expectation of **Rmb20 million** per hospital for equipment trade-ins in 2025 [3][51]. - **Stimulus Growth**: 48% of respondents expect an increase in stimulus funds compared to 2024, indicating ongoing governmental support for medical equipment procurement [51][53]. DRG Impact - **Stabilization of DRG Effects**: Approximately 90% of respondents expect the impact of DRG to stabilize by the first half of 2026, with clinical labs being the slowest to adapt [4][23][24]. - **IVD Sector Challenges**: The In-Vitro Diagnostics (IVD) sector is facing a "double-hit" in 2025, with expectations of recovery starting from 1H26 [37][38]. Domestic Substitution - **Cost Reduction**: Surgery costs have decreased by **13% year-over-year**, primarily due to increased use of domestic products and price reductions in medical consumables [30][35]. - **Market Dynamics**: Leading domestic manufacturers like Mindray, United Imaging, and MicroPort MedBot are gaining market share and challenging multinational corporations (MNCs) on quality and physician preference [1][5][47]. Brand Preference and Market Competition - **Domestic Brand Growth**: The survey indicates a significant shift towards domestic brands in imaging and IVD, with Mindray emerging as a leader in hematology analyzers and total lab automation solutions [45][47]. - **Competitive Landscape**: While MNCs maintain dominance in high-end niches, domestic players are rapidly closing the gap, particularly in high-volume segments [44][47]. Operational Dynamics - **Generics Usage**: 74% of prescriptions are for generics when available, indicating limited room for cost savings through switching from branded drugs [56]. - **Multi-Site Practices**: 14% of surgeons have increased multi-site practice activities, with 76% expecting this trend to continue, potentially benefiting private hospitals [66][69]. Financial Metrics - **Accounts Receivable Days**: The average receivable days for public medical insurance payments have decreased to **57 days** in 2025 from **61 days** in 2024, with notable improvements in Tier 1 and Tier 2 cities [71][72]. Conclusion - The China healthcare market is experiencing a transformative phase characterized by the integration of AI, a shift towards domestic products, and stabilization of DRG impacts. The ongoing support from the government and the evolving competitive landscape suggest a promising outlook for domestic manufacturers and healthcare providers in the coming years [1][5][47].

Summary of the Conference Call Transcript Industry Overview - The conference call focuses on the **insulin industry in China**, highlighting the significant opportunities for **domestic substitution** following two rounds of **Volume-Based Procurement (VBP)** [1][1]. Key Companies Discussed 1. **Gan & Lee Pharmaceuticals** - Revenue for 3Q25 was **Rmb980 million**, reflecting a **5% year-over-year increase**. However, this was below Goldman Sachs estimates of **Rmb1,140 million** [8][8]. - Net profit for the same period was **Rmb235 million**, also missing estimates of **Rmb309 million** [8][8]. - The company is optimistic about achieving its full-year net profit target of **Rmb1.1 billion**, implying **Rmb280 million** in net profit for 4Q25, supported by expected orders from Brazil [8][8]. - Revised price target (TP) is set at **Rmb73**, down from **Rmb77**, with a **Buy** rating maintained [8][8]. 2. **Tonghua Dongbao (THDB)** - THDB reported 3Q25 revenue of **Rmb806 million**, a **14% year-over-year increase**, exceeding Goldman Sachs estimates of **Rmb724 million** [17][17]. - Net profit surged to **Rmb984 million**, a **500% year-over-year increase**, driven by investment gains from divesting Amoytop Biotech [17][17]. - The company’s sales performance was bolstered by expanding market share in insulin analog products [17][17]. - Revised price target is **Rmb10**, up from **Rmb9**, with a **Neutral** rating maintained [17][17]. Market Dynamics - The localization rates for insulin analogs have increased in 2Q25 compared to 1Q25: - **Insulin glargine**: 51% (unchanged) - **Insulin aspart premix**: 22% (up from 19%) - **Insulin aspart**: 17% (up from 15%) [1][1]. - There is a belief that there is still ample market space for further domestic substitution in the coming years [1][1]. Growth Drivers - **Gan & Lee** is focusing on: - Exporting insulin biosimilars to the US and EU - Continuing to substitute imports in the Chinese market - Expansion into emerging markets [19][19]. - **THDB** is promoting its new third-generation insulin products in private hospitals and pharmacies, which are not affected by the VBP policy [20][20]. Financial Estimates - **Gan & Lee** updated estimates for 2025 to 2027 show a slight decrease in revenue and net profit projections: - 2025 Revenue: **Rmb4,202 million** (down from **Rmb4,400 million**) - 2025 Net Profit: **Rmb1,101 million** (down from **Rmb1,173 million**) [16][16]. - **THDB** updated estimates show significant increases: - 2025 Revenue: **Rmb2,762 million** (up from **Rmb2,689 million**) - 2025 Net Profit: **Rmb1,281 million** (up from **Rmb408 million**) [18][18]. Risks and Catalysts - **Gan & Lee** faces risks such as slower-than-expected launches of insulin biosimilars in the US and R&D progress [23][23]. - **THDB** has upside risks related to stronger-than-expected ramp-up of its third-generation insulin products and faster approval of insulin biosimilars in the US [24][24]. Conclusion - The insulin market in China is experiencing significant growth opportunities, particularly for domestic manufacturers like Gan & Lee and Tonghua Dongbao. Both companies are positioned to benefit from increased localization and market share expansion, despite facing various risks and challenges in the evolving regulatory landscape.

Group 1 - The Shanghai Stock Exchange's Sci-Tech Innovation Board semiconductor materials and equipment index decreased by 0.45% as of October 23, 10:38 AM, with mixed performance among constituent stocks [1] - Top gainers included Tuojing Technology up by 3.88%, Xinyi Chang up by 3.21%, and Shengmei Shanghai up by 1.5%, while leading decliners were Shenkong Co. down by 5.82%, Jingsheng Co. down by 3.11%, and Huahai Chengke down by 3.02% [1] - The Sci-Tech semiconductor ETF (588170) fell by 0.51% with an intraday turnover of 4.44% and a transaction volume of 168 million yuan [1] Group 2 - The latest scale of the Sci-Tech semiconductor ETF (588170) reached 3.814 billion yuan, marking a new high since its inception [2] - The ETF and its linked funds track the Sci-Tech Innovation Board semiconductor materials and equipment index, focusing on semiconductor equipment (61%) and semiconductor materials (23%) [2] - The semiconductor equipment and materials industry is a significant area for domestic substitution, characterized by low domestic substitution rates and high ceilings for domestic replacement, benefiting from the expansion of semiconductor demand driven by the AI revolution, technology restructuring, and mergers and acquisitions [2]

Core Insights - The report highlights a mixed performance in the photovoltaic (PV) industry, with significant growth in component exports but a decline in new installations in August 2025 [1][2][3] Group 1: Domestic PV Installations - In August 2025, domestic PV installations reached 7.4GW, showing a year-on-year decrease of 55.3% and a month-on-month decrease of 33.3% [2] - Cumulatively, from January to August 2025, new PV installations totaled 230.61GW, reflecting a year-on-year increase of 64.7% [2] Group 2: Component Exports - In August 2025, the export value of PV components was 20.95 billion yuan, marking a year-on-year increase of 20.4% and a month-on-month increase of 31.9% [1][2] - The cumulative export value from January to August 2025 was 132.21 billion yuan, which is a year-on-year decrease of 18.0% [1][2] - In July 2025, the domestic PV component export volume was 21.25GW, showing a year-on-year increase of 8% but a month-on-month decrease of 2% [1][2] Group 3: Inverter Exports - The export value of inverters in August 2025 was 6.29 billion yuan, with a year-on-year increase of 2.2% but a month-on-month decrease of 3.4% [3] - Cumulatively, from January to August 2025, the total export value of inverters was 43.4 billion yuan, reflecting a year-on-year increase of 8.0% [3] - Exports to different regions showed varied performance, with significant growth in Oceania (year-on-year increase of 245.9%) but declines in North America (year-on-year decrease of 24.1%) [3] Group 4: Solar Power Generation - In August 2025, solar power generation reached 53.82 billion kWh, representing a year-on-year growth of 15.9% [3] - Solar power accounted for 5.75% of the total industrial power generation in the country, with a slight month-on-month decrease of 0.29 percentage points [3] - The total power generation in August 2025 was 936.3 billion kWh, with various energy sources showing different growth rates [3] Group 5: Recommended Companies - Companies recommended for investment include Aiko Solar, Longi Green Energy, Daqo New Energy, and others focusing on various segments of the PV industry [4]

Group 1: China's Market Comeback - Global money managers are significantly returning to China's equity market, driven by a strong stock rally and advancements in high-tech industries, particularly AI and semiconductors [2][3] - Chinese hardware makers, such as Cambricon Technologies, SMIC, and Hygon Information Technology, are experiencing substantial gains in the A-share market due to soaring demand for AI-driven cloud computing [4] - Alibaba Group has seen its shares surge following plans to ramp up AI spending, with global AI investment expected to reach approximately $4 trillion over the next five years [4] Group 2: Asia's Equity Capital Markets - Asia's equity capital markets are thriving, with Hong Kong and India leading in deal activity, marking a standout year for ECM [5] - India is experiencing a rebound in investments, with senior dealmakers earning more than their counterparts in Singapore and Hong Kong, as global firms increase pay to attract talent [5] Group 3: UK Economic Outlook - The UK labor market is showing signs of cooling, with job postings falling by 1.3% year-on-year and 2.1% month-on-month, reflecting growing employer caution [6] - Despite higher vacancies than in January, businesses are concerned about potential tax rises and increased social security contributions, impacting hiring appetite [6] Group 4: Geopolitical Concerns - Ukrainian President Volodymyr Zelenskyy has warned of an impending AI arms race, emphasizing the need for global regulations on military AI and drone technology [7][8] - Zelenskyy highlighted the urgency of establishing rules for AI in weapons, comparing it to the necessity of preventing the spread of nuclear weapons [8]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Semi-Tech Group Co., Ltd.* 賽美特信息集團股份有限公司 (A joint stock company incorporated in the People's Republic of China with ...

Summary of Conference Call on China Healthcare and Life Science Tools Industry Overview - The conference call focuses on the **China Healthcare** sector, specifically the **Life Science Tools** industry, highlighting the potential for growth driven by a robust out-licensing wave and anticipated US Fed rate cuts [1][2][24]. Core Companies Discussed - **Acrobiosystems** (Ticker: 301080.SZ) - Initiated with an **Overweight** rating and a price target of **Rmb102.50** [11][8]. - Positioned as an industry leader in protein-based life science products, benefiting from strong R&D demand [11][32]. - **Tofflon Science & Technology** (Ticker: 300171.SZ) - Initiated with an **Equal-weight** rating and a price target of **Rmb16.77** [14][16]. - Recognized for its domestic leadership in life sciences equipment supply but viewed as fairly valued due to moderate end-market demand [14][15]. Key Insights and Arguments - **Market Dynamics**: A new bullish cycle is emerging in China's life science sector, driven by innovative asset out-licensing, increased R&D activity, and a recovery in domestic biotech funding [2][24]. - **Investment Preferences**: Preference for companies directly tied to early-stage drug discovery over those focused on late-stage production due to better growth visibility and earnings potential [3][4]. - **Valuation and Growth**: - Acrobiosystems is considered undervalued with a **2026e P/E of 34x** and a **55% earnings CAGR** from 2024-2027, significantly below the peer average [11][32]. - Tofflon, while showing a **42% earnings CAGR**, is seen as fairly valued due to challenges in the equipment supply segment [15][33]. Risks and Opportunities - **Key Risks**: - Geopolitical uncertainties, regulatory changes, price competition, and IP risks are highlighted as potential downsides [5][42]. - Upside potential includes faster domestic substitution and stronger demand from a growing R&D drug pipeline [5][42]. - **Domestic Substitution**: The trend towards domestic substitution in pharmaceuticals is gaining momentum, driven by supply chain security concerns post-COVID [28][67]. However, challenges remain, particularly for high-end bioprocessing equipment due to longer replacement cycles and quality concerns [68][69]. Financial Metrics - **Acrobiosystems**: - 2024 Revenue: **Rmb645 million**, with a projected growth to **Rmb1,504 million** by 2027 [12]. - Gross Margin: **90.9%** in 2024, indicating strong profitability [31]. - **Tofflon**: - 2024 Revenue: **Rmb5,010 million**, expected to grow to **Rmb6,241 million** by 2027 [16]. - Gross Margin: **29.2%**, reflecting the lower margin nature of its equipment business [31]. Market Trends - **R&D Investment Growth**: Global drug R&D expenses are projected to rise from **US$644 billion in 2024** to **US$879 billion by 2031**, with China's growth expected to outpace this at a **6.9% CAGR** [46]. - **Biological Reagents Market**: The global biological reagents market is anticipated to grow from **US$25 billion in 2024** to **US$37 billion by 2031**, with China's market expanding at a **16.7% CAGR** [56]. Conclusion - The life science tools sector in China is poised for significant growth, driven by favorable market conditions and strong demand for innovative drug development. Acrobiosystems and Tofflon represent key players with distinct market positions, though they face varying challenges and opportunities in the evolving landscape.